8 results on '"Amadou T. Konaté"'
Search Results
2. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age
- Author
-
Jerald C. Sadoff, Edith C. Bougouma, Noelie Henri, Alfred B. Tiono, Souleymane Sanon, Sodiomon B. Sirima, Amidou Diarra, Valerie Brown, Amadou T. Konaté, Edison Wiesken, Alphonse Ouedraogo, Issa Nebie, Isabella Versteege, Désiré Kargougou, Jenny Hendriks, Issiaka Soulama, Nora L. Watson, Espérance Ouédraogo, Adama Gansané, Jean Baptiste Yaro, Youssouf Kaboré, David T. Kangoye, and Maria Grazia Pau
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Plasmodium falciparum ,Population ,Dose-Response Relationship, Immunologic ,Immunization, Secondary ,Protozoan Proteins ,lcsh:Medicine ,Biology ,Adenoviridae ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Burkina Faso ,medicine ,Humans ,030212 general & internal medicine ,Malaria, Falciparum ,education ,Adverse effect ,lcsh:Science ,030304 developmental biology ,0303 health sciences ,education.field_of_study ,Multidisciplinary ,Reactogenicity ,Malaria vaccine ,Immunogenicity ,lcsh:R ,Antibody titer ,Middle Aged ,3. Good health ,Vaccination ,Immunology ,Female ,lcsh:Q ,Research Article - Abstract
Background Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naive adults and showed that the vaccine was safe. The aim of this study is to assess the safety and immunogenicity of ascending dosages in sub Saharan Africa. Methods A double blind, randomized, controlled, dose escalation, phase Ib trial was conducted in a rural area of Balonghin, the Sapone health district (Burkina Faso). Forty-eight healthy adults aged 18-45 years were randomized into 4 cohorts of 12 to receive three vaccine doses (day 0, 28 and 84) of 10(9), 10(10), 5X10(10), 10(11) vp of Ad35.CS.01 or normal saline by intra muscular injection. Subjects were monitored carefully during the 14 days following each vaccination for non serious adverse events. Severe and serious adverse events were collected throughout the participant study duration (12 months from the first vaccination). Humoral and cellular immune responses were measured on study days 0, 28, 56, 84, 112 and 140. Results Of the forty-eight subjects enrolled, forty-four (91.7%) received all three scheduled vaccine doses. Local reactions, all of mild severity, occurred in thirteen (27.1%) subjects. Severe (grade 3) laboratory abnormalities occurred in five (10.4%) subjects. One serious adverse event was reported and attributed to infection judged unrelated to vaccine. The vaccine induced both antibody titers and CD8 T cells producing IFNγ and TNFα with specificity to CS while eliciting modest neutralizing antibody responses against Ad35. Conclusion Study vaccine Ad35.CS.01 at four different dose levels was well-tolerated and modestly immunogenic in this population. These results suggest that Ad35.CS.01 should be further investigated for preliminary efficacy in human challenge models and as part of heterologous prime-boost vaccination strategies. Trial registration ClinicalTrials.gov NCT01018459 http://clinicaltrials.gov/ct2/show/NCT01018459.
- Published
- 2013
3. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso
- Author
-
Alfred B. Tiono, Espérance Ouédraogo, Alphonse Ouedraogo, Adama Gansané, Amathe Ouedraogo, Issa Nebie, Megan Sanza, Edith C. Bougouma, Amadou T. Konaté, Jean Baptiste Yaro, Tina J. T. Dube, Nora L. Watson, Souleymane Sanon, Sodiomon B. Sirima, Amidou Diarra, and Issiaka Soulama
- Subjects
Male ,Pediatrics ,Endemic Diseases ,Cross-sectional study ,Epidemiology ,lcsh:Medicine ,Parasitemia ,Parasite Load ,Cohort Studies ,Prevalence ,Prospective Studies ,Malaria, Falciparum ,lcsh:Science ,health care economics and organizations ,Multidisciplinary ,Malaria vaccine ,Incidence (epidemiology) ,Incidence ,Vaccination ,Plasmodium Falciparum ,Infectious Diseases ,Child, Preschool ,population characteristics ,Medicine ,Female ,Seasons ,geographic locations ,Cohort study ,Research Article ,medicine.medical_specialty ,Infectious Disease Epidemiology ,Environmental health ,Vaccine Development ,Burkina Faso ,parasitic diseases ,medicine ,Parasitic Diseases ,Humans ,business.industry ,lcsh:R ,Immunity ,Infant, Newborn ,Tropical Diseases (Non-Neglected) ,Infant ,medicine.disease ,Malaria ,Cross-Sectional Studies ,Clinical Immunology ,lcsh:Q ,Rural area ,Morbidity ,business - Abstract
Background Malariometric parameters are often primary endpoints of efficacy trials of malaria vaccine candidates. This study aims to describe the epidemiology of malaria prior to the conduct of a series of drug and vaccine trials in a rural area of Burkina Faso. Methods Malaria incidence was prospectively evaluated over one year follow-up among two cohorts of children aged 0–5 years living in the Saponé health district. The parents of 1089 children comprising a passive case detection cohort were encouraged to seek care from the local health clinic at any time their child felt sick. Among this cohort, 555 children were randomly selected for inclusion in an active surveillance sub-cohort evaluated for clinical malaria during twice weekly home visits. Malaria prevalence was evaluated by cross-sectional survey during the low and high transmission seasons. Results Number of episodes per child ranged from 0 to 6 per year. Cumulative incidence was 67.4% in the passive and 86.2% in the active cohort and was highest among children 0–1 years. Clinical malaria prevalence was 9.8% in the low and 13.0% in the high season (p>0.05). Median days to first malaria episode ranged from 187 (95% CI 180–193) among children 0–1 years to 228 (95% CI 212, 242) among children 4–5 years. The alternative parasite thresholds for the malaria case definition that achieved optimal sensitivity and specificity (70–80%) were 3150 parasites/µl in the high and 1350 parasites/µl in the low season. Conclusion Clinical malaria burden was highest among the youngest age group children, who may represent the most appropriate target population for malaria vaccine candidate development. The pyrogenic threshold of parasitaemia varied markedly by season, suggesting a value for alternative parasitaemia levels in the malaria case defintion. Regional epidemiology of malaria described, Sapone area field centers are positioned for future conduct of malaria vaccine trials.
- Published
- 2013
4. Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
- Author
-
Sodiomon B. Sirima, Alfred B. Tiono, Alphonse Ouédraogo, Amidou Diarra, André Lin Ouédraogo, Jean Baptiste Yaro, Espérance Ouédraogo, Adama Gansané, Edith C. Bougouma, Amadou T. Konaté, Youssouf Kaboré, Abdoulaye Traoré, Chilengi Roma, Issiaka Soulama, Adrian J. F. Luty, Pierre Druilhe, Simon Cousens, and Issa Nébié
- Subjects
Multidisciplinary ,Science ,lcsh:R ,Medicine ,lcsh:Medicine ,Correction ,lcsh:Q ,lcsh:Science - Published
- 2010
5. Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
- Author
-
Sodiomon B Sirima, Alfred B Tiono, Alphonse Ouédraogo, Amidou Diarra, André Lin Ouédraogo, Jean Baptiste Yaro, Espérance Ouédraogo, Adama Gansané, Edith C Bougouma, Amadou T Konaté, Youssouf Kaboré, Abdoulaye Traoré, Roma Chilengi, Issiaka Soulama, Adrian J F Luty, Pierre Druilhe, Simon Cousens, and Issa Nébié
- Subjects
medicine.medical_specialty ,Hepatitis B vaccine ,Time Factors ,Plasmodium falciparum ,Pediatrics and Child Health ,Public Health and Epidemiology ,Protozoan Proteins ,lcsh:Medicine ,Antigens, Protozoan ,Double-Blind Method ,Internal medicine ,parasitic diseases ,Burkina Faso ,Malaria Vaccines ,Medicine ,Humans ,lcsh:Science ,Adverse effect ,Multidisciplinary ,Reactogenicity ,Dose-Response Relationship, Drug ,business.industry ,Malaria vaccine ,Merozoites ,Immunogenicity ,lcsh:R ,Infant ,medicine.disease ,Malaria ,Vaccination ,Treatment Outcome ,Tolerability ,Research Design ,Child, Preschool ,Immunology ,Immunology/Immune Response ,lcsh:Q ,business ,Peptides ,Research Article - Abstract
BACKGROUND:A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult volunteers in Burkina Faso confirmed that the vaccine was safe. The aim of this study was to assess the safety and immunogenicity of this vaccine candidate in children aged 12-24 months living in malaria endemic area of Burkina Faso. METHODS:The study was a double-blind, randomized, controlled, dose escalation phase Ib trial, designed to assess the safety, reactogenicity and immunogenicity of three doses of either 15 or 30 microg of MSP3-LSP adsorbed on aluminum hydroxide in 45 children 12 to 24 months of age randomized into three equal groups. Each group received 3 vaccine doses (on days 0, 28 and 56) of either 15 microg of MSP3-LSP, 30 microg of MSP3-LSP or of the Engerix B hepatitis B vaccine. Children were visited at home daily for the 6 days following each vaccination to solicit symptoms which might be related to vaccination. Serious adverse events occurring during the study period (1 year) were recorded. Antibody responses to MSP3-LSP were measured on days 0, 28, 56 and 84. RESULTS:All 45 enrolled children received three MSP3 vaccine doses. No serious adverse events were reported. Most of the adverse events reported were mild to moderate in severity. The only reported local symptoms with grade 3 severity were swelling and induration, with an apparently dose related response. All grade 3 adverse events resolved without any sequelae. Both MSP3 doses regimens were able to elicit high levels of anti-MSP3 specific IgG1 and IgG3 antibodies in the volunteers with very little or no increase in IgG2, IgG4 and IgM classes: i.e. vaccination induced predominantly the isotypes involved in the monocyte-dependent mechanism of P. falciparum parasite-killing. CONCLUSION:Our results support the promise of MSP3-LSP as a malaria vaccine candidate, both in terms of tolerability and of immunogenicity. Further assessment of the efficacy of this vaccine is recommended. TRIAL REGISTRATION:ClinicalTrials.gov NCT00452088.
- Published
- 2009
6. Morbidity from Malaria in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria: A Randomised Trial
- Author
-
Amidou Diarra, Amidou Ouedraogo, David T. Kangoye, Adama Gansané, Issiaka Soulama, Sodiomon B. Sirima, Alfred B. Tiono, Youssouf Kaboré, Daniel Chandramohan, Amadou T. Konaté, Espérance Ouédraogo, Alphonse Ouedraogo, Issa Ouedraogo, Diadier Diallo, Brian Greenwood, Jean Baptiste Yaro, Paul Milligan, and Simon Cousens
- Subjects
Male ,Travel-Associated Diseases ,Pediatrics ,Epidemiology ,medicine.medical_treatment ,lcsh:Medicine ,Kaplan-Meier Estimate ,Mosquitoes ,Prevalence ,Malaria, Falciparum ,lcsh:Science ,Wasting ,Mosquito Nets ,Multidisciplinary ,biology ,Incidence ,Incidence (epidemiology) ,Child Health ,Anemia ,Drug Combinations ,Infectious Diseases ,Pyrimethamine ,Treatment Outcome ,Child, Preschool ,Medicine ,Drug Therapy, Combination ,Female ,Public Health ,Seasons ,medicine.symptom ,Research Article ,medicine.drug ,Drugs and Devices ,medicine.medical_specialty ,Drug Research and Development ,Infectious Disease Control ,Clinical Research Design ,Sulfadoxine ,Plasmodium falciparum ,Amodiaquine ,Drug Administration Schedule ,Antimalarials ,Double-Blind Method ,Burkina Faso ,parasitic diseases ,Parasitic Diseases ,medicine ,Humans ,Clinical Trials ,business.industry ,Body Weight ,lcsh:R ,Tropical Diseases (Non-Neglected) ,Infant ,Vectors and Hosts ,biology.organism_classification ,medicine.disease ,Malaria ,Malnutrition ,lcsh:Q ,Preventive Medicine ,Morbidity ,business ,Follow-Up Studies - Abstract
BACKGROUND: Interventions that reduce exposure to malaria infection may lead to delayed malaria morbidity and mortality. We investigated whether intermittent preventive treatment of malaria in children (IPTc) was associated with an increase in the incidence of malaria after cessation of the intervention. METHODS: An individually randomised, trial of IPTc, comparing three courses of sulphadoxine pyrimethamine (SP) plus amodiaquine (AQ) with placebos was implemented in children aged 3-59 months during the 2008 malaria transmission season in Burkina Faso. All children in the trial were given a long lasting insecticide treated net; 1509 children received SP+AQ and 1505 received placebos. Passive surveillance for malaria was maintained until the end of the subsequent malaria transmission season in 2009, and active surveillance for malaria infection, anaemia and malnutrition was conducted. RESULTS: On thousand, four hundred and sixteen children (93.8%) and 1399 children (93.0%) initially enrolled in the intervention and control arms of the trial respectively were followed during the 2009 malaria transmission season. During the period July 2009 to November 2009, incidence rates of clinical malaria were 3.84 (95%CI; 3.67-4.02) and 3.45 (95%CI; 3.29-3.62) episodes per child during the follow up period in children who had previously received IPT or placebos, indicating a small increase in risk for children in the former intervention arm (IRR = 1.12; 95%CI 1.04-1.20) (P = 0.003). Children who had received SP+AQ had a lower prevalence of malaria infection (adjusted PR: 0.88 95%CI: 0.79-0.98) (P = 0.04) but they had a higher parasite density (P = 0.001) if they were infected. There was no evidence that the risks of moderately severe anaemia (Hb
- Published
- 2011
7. Intermittent preventive treatment of malaria in children: a qualitative study of community perceptions and recommendations in Burkina Faso and Mali.
- Author
-
Catherine Pitt, Halimatou Diawara, Dimlawendé J Ouédraogo, Samba Diarra, Habibou Kaboré, Kibsbila Kouéla, Abdoulaye Traoré, Alassane Dicko, Amadou T Konaté, Daniel Chandramohan, Diadier A Diallo, Brian Greenwood, and Lesong Conteh
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Intermittent preventive treatment of malaria in children (IPTc) is a highly efficacious method of malaria control where malaria transmission is highly seasonal. However, no studies published to date have examined community perceptions of IPTc. METHODS: A qualitative study was undertaken in parallel with a double-blind, placebo-controlled, randomized trial of IPTc conducted in Mali and Burkina Faso in 2008-2009 to assess community perceptions of and recommendations for IPTc. Caregivers and community health workers (CHWs) were purposively sampled. Seventy-two in-depth individual interviews and 23 focus group discussions were conducted. FINDINGS: Widespread perceptions of health benefits for children led to enthusiasm for the trial and for IPTc specifically. Trust in and respect for those providing the tablets and a sense of obligation to the community to participate in sanctioned activities favoured initial adoption. IPTc fits in well with existing understandings of childhood illness. Participants did not express concerns about the specific drugs used for IPTc or about providing tablets to children without symptoms of malaria. There was no evidence that IPTc was perceived as a substitute for bed net usage, nor did it inhibit care seeking. Participants recommended that distribution be "closer to the population", but expressed concern over caregivers' ability to administer tablets at home. CONCLUSIONS: The trial context mediated perceptions of IPTc. Nonetheless, the results indicate that community perceptions of IPTc in the settings studied were largely favourable and that the delivery strategy rather than the tablets themselves presented the main areas of concern for caregivers and CHWs. The study identifies a number of key questions to consider in planning an IPTc distribution strategy. Single-dose formulations could increase the success of IPTc implementation, as could integration of IPTc within a package of activities, such as bed net distribution and free curative care, for which demand is already high.
- Published
- 2012
- Full Text
- View/download PDF
8. Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
- Author
-
Amadou T Konaté, Jean Baptiste Yaro, Amidou Z Ouédraogo, Amidou Diarra, Adama Gansané, Issiaka Soulama, David T Kangoyé, Youssouf Kaboré, Espérance Ouédraogo, Alphonse Ouédraogo, Alfred B Tiono, Issa N Ouédraogo, Daniel Chandramohan, Simon Cousens, Paul J Milligan, Sodiomon B Sirima, Brian M Greenwood, and Diadier A Diallo
- Subjects
Medicine ,Science - Abstract
Interventions that reduce exposure to malaria infection may lead to delayed malaria morbidity and mortality. We investigated whether intermittent preventive treatment of malaria in children (IPTc) was associated with an increase in the incidence of malaria after cessation of the intervention.An individually randomised, trial of IPTc, comparing three courses of sulphadoxine pyrimethamine (SP) plus amodiaquine (AQ) with placebos was implemented in children aged 3-59 months during the 2008 malaria transmission season in Burkina Faso. All children in the trial were given a long lasting insecticide treated net; 1509 children received SP+AQ and 1505 received placebos. Passive surveillance for malaria was maintained until the end of the subsequent malaria transmission season in 2009, and active surveillance for malaria infection, anaemia and malnutrition was conducted.On thousand, four hundred and sixteen children (93.8%) and 1399 children (93.0%) initially enrolled in the intervention and control arms of the trial respectively were followed during the 2009 malaria transmission season. During the period July 2009 to November 2009, incidence rates of clinical malaria were 3.84 (95%CI; 3.67-4.02) and 3.45 (95%CI; 3.29-3.62) episodes per child during the follow up period in children who had previously received IPT or placebos, indicating a small increase in risk for children in the former intervention arm (IRR = 1.12; 95%CI 1.04-1.20) (P = 0.003). Children who had received SP+AQ had a lower prevalence of malaria infection (adjusted PR: 0.88 95%CI: 0.79-0.98) (P = 0.04) but they had a higher parasite density (P = 0.001) if they were infected. There was no evidence that the risks of moderately severe anaemia (Hb
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.